What Is the Potential Growth Expected for the Opdivo (nivolumab) Market?
The global Opdivo (nivolumab) market has notably grown over recent years. The market size experienced a surge from $7,709.49 million in 2024 to an anticipated $8,335.54 million in 2025, growing at a compound annual growth rate (CAGR) of 8.1%. This growth trajectory during the historical period is primarily attributable to the rising prevalence of cancer, the expansion in research and development proficiencies, and the growth in healthcare expenditure for capital equipment.
Furthermore, the market size is projected to witness robust growth in the coming years, escalating to $11,281.56 million in 2029 at a CAGR of 7.9%. Factors propelling this forecasted growth include the growing acceptance of immunotherapy, a deeper understanding of its benefits, and the increasing application of nivolumab for various indications. Key trends projected to shape the market during the forecast period include product innovation, geographic market expansion, ongoing clinical trials, a growing trend for personalized medicine, and advancements in cancer research.
Get Your Free Sample of The Global Opdivo (nivolumab) Global Market Report 2025:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp
What Are the Key Drivers of the Opdivo (nivolumab) Market Growth?
The market growth is principally propelled by the increasing incidence of non-small lung cancer. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases, with increasing incidences primarily attributed to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo works by blocking the PD-1 receptor on immune cells, thereby augmenting the body’s immune response to recognize and attack cancer cells. In 2024, the American Cancer Society reported that 234,580 new cases of lung cancer were diagnosed in the US, of which 80% were NSCLC, marking an increase compared to the 238,340 diagnosed cases in 2023.
What Are the Major Market Segments for Opdivo (nivolumab)?
1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL
2) By Dosage: Injection; Solution; Other Dosages
3) By Demographic: Adult; Pediatric
4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
5) By End-User: Hospitals; Clinics; Other End Users
Unlock more valuable insights and swift delivery options for the market report:
https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report
Which Companies Have the Largest Market Share in the Opdivo (nivolumab) Market?
Major companies operating in the Opdivo (nivolumab) market include Bristol-Myers Squibb and Ono Pharmaceutical.
What Trends Are Shaping the Opdivo (nivolumab) Market Landscape?
The key trend in the Opdivo (nivolumab) market is developing combination therapies to elevate treatment efficacy and expand its applications across multiple cancer types. Combination approaches aim to circumnavigate resistance mechanisms and provide comprehensive treatment options for advanced cancer patients.
How Is the Regional Opdivo (nivolumab) Market Performance?
North America was the largest region in the Opdivo (nivolumab) market in 2024. The fastest-growing region in the forecast period is expected to be Asia-Pacific. The regions covered in the Opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Opdivo (nivolumab) Global Market Report 2025 Offer?
The Opdivo (nivolumab) Global Market Report 2025 from The Business Research Company provides global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities. Opdivo (nivolumab) is a prescription medication that belongs to a class of drugs known as immune checkpoint inhibitors, specifically targeting programmed death-1 (PD-1) receptors. It is a type of immunotherapy used to treat various cancers by enhancing the immune system’s capacity to detect and destroy cancer cells.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19914
About The Business Research Company
We offer over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company is known for comprehensive, data-rich research and insights. Equipped with 1,500,000 datasets, combined with in-depth secondary research and unique insights from industry leaders, we provide the essential information to stay ahead.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
